Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $7.85 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
CohBar Inc had its IPO on 2015-01-28 under the ticker symbol CWBR.
The company operates in the Healthcare sector and Biotechnology industry. CohBar Inc has a staff strength of 9 employees.
Shares of CohBar Inc opened at $2.68 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $2.68 - $2.9, and closed at $2.86.
This is a +5.93% increase from the previous day's closing price.
A total volume of 67,586 shares were traded at the close of the day’s session.
In the last one week, shares of CohBar Inc have slipped by -20.99%.
CohBar Inc's Key Ratios
CohBar Inc has a market cap of $7.85 million, indicating a price to book ratio of 0.2652 and a price to sales ratio of 0.
In the last 12-months CohBar Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-11307156. The EBITDA ratio measures CohBar Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, CohBar Inc’s operating margin was 0% while its return on assets stood at -37.01% with a return of equity of -60.7%.
In Q1, CohBar Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
CohBar Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.85 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into CohBar Inc’s profitability.
CohBar Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.8958. Its price to sales ratio in the trailing 12-months stood at 0.
CohBar Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $14.40 million
- Total Liabilities
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
CohBar Inc ended 2023 with $14.40 million in total assets and $0 in total liabilities. Its intangible assets were valued at $14.40 million while shareholder equity stood at $13.50 million.
CohBar Inc ended 2023 with $0 in deferred long-term liabilities, $898541.00 in other current liabilities, 2907.00 in common stock, $-99075121.00 in retained earnings and $0 in goodwill. Its cash balance stood at $5.39 million and cash and short-term investments were $14.08 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
CohBar Inc’s total current assets stands at $14.32 million while long-term investments were $0 and short-term investments were $8.69 million. Its net receivables were $0 compared to accounts payable of $532423.00 and inventory worth $0.
In 2023, CohBar Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, CohBar Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
CohBar Inc stock is currently trading at $2.86 per share. It touched a 52-week high of $7.5 and a 52-week low of $7.5. Analysts tracking the stock have a 12-month average target price of $18.
Its 50-day moving average was $1.94 and 200-day moving average was $2.4 The short ratio stood at 5.6 indicating a short percent outstanding of 0%.
Around 1504.9% of the company’s stock are held by insiders while 484.6% are held by institutions.
Frequently Asked Questions About CohBar Inc
Similar Industry Stocks (Biotechnology)
CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.